Tianjin Zhong Xin Pharmaceutical Group Corp. Ltd. revenue breakdown overview

Tianjin Zhong Xin Pharmaceutical Group Corp. Ltd. revenue for the last year amounted to 1.03 B EUR, the most of which — 746.32 M EUR — came from its highest performing source at the moment, Chinese Patent Medicine, the year earlier bringing 784.27 M EUR. The greatest contribution to the revenue figure was made by China — last year it brought Tianjin Zhong Xin Pharmaceutical Group Corp. Ltd. 1.04 B EUR, and the year before that — 1.14 B EUR.